
Assessed for eligibility
(n = 343)
Screening failures
(n = 57)
Randomized
(n = 286)
Allocation
Allocated to the Clarithromycin group (n = 143)
• Received ≥ 1 cycle of the allocated intervention (n = 135)
• Received < 1 cycle of the allocated intervention (n = 8)
Allocated to the control group (n = 143)
• Received ≥ 1 cycle of the allocated intervention (n = 140)
• Received < 1 cycle of the allocated intervention (n = 3)
Follow-up
Discontinued intervention (n = 108)
• Progressive disease (n = 34)
• Toxicity (n = 27)
• Informed consent withdrawal (n = 4)
• Death (n = 24)
• Physician decisión (n = 5)
• Development of new comorbidities (n = 14)
Discontinued intervention (n = 82)
• Progressive disease (n = 39)
• Toxicity (n = 16)
• Informed consent withdrawal (n = 1)
• Death (n = 10)
• Physician decisión (n = 2)
• Development of new comorbidities (n = 13)
Analysis
Intent-to-treat analysis (n = 143)
• Excluded from safety analysis (n = 0)
Intent-to-treat analysis (n = 143)
• Excluded from safety analysis (n = 0)